| 
						China restricts opioid in tighter 
						painkiller controls
   Send a link to a friend 
		[August 08, 2019]  
		BEIJING (Reuters) - China has imposed new 
		restrictions on the opioid oxycodone, its drug regulator said, as the 
		country tightens control of its painkillers industry in the battle 
		against drug addiction. | 
        
            | 
			
			 Oxycodone, among the heavy-duty painkillers blamed for the deadly 
			opioid crisis in the United States, will be classified as a 
			pyschotropic drug in some formulations and require more approvals to 
			produce or prescribe them, the National Medical Products 
			Administration said late on Tuesday. 
 Oral solid formulations with more than 5 mg of oxycodone per unit 
			will be categorized as first-class psychotropic drugs from Sept. 1, 
			the agency said.
 
 Formulations with less than 5 mg of oxycodone per unit, as well as 
			composite oral solid formulations with buprenorphine and naloxone, 
			will be categorized as second-class psychotropic drugs at the same 
			time, it said.
 
			
			 
			Under current laws, first class pyschotropic drugs are banned from 
			sale to retail customers, and second class products cannot be sold 
			to minors.
 
 The laws also require state approvals for pharmaceutical firms to 
			use first-class psychotropic drugs as active ingredients in their 
			products, and hospitals can only purchase these products from 
			suppliers designated by authorities.
 
			
            [to top of second column] | 
            
			 
			Chinese media have voiced concern over oxycodone addiction in the 
			country. Financial magazine Caixin reporting in March that opioid 
			users accounted for 38.1% of the 2.5 million people who were known 
			to have abused drugs in China in 2016. 
			Liu Xiaodong, a professor at China Pharmaceutical University, said 
			the tighter controls would help to reduce the illegal use of 
			oxycodone.
 "Many medicines are useful, but abusing them would turn them into 
			(illicit) drugs," Liu told Reuters.
 
 Narcotics produced in China have become a contentious issue in 
			relations with the United States.
 
 This month, President Donald Trump accused his Chinese counterpart 
			Xi Jinping of failing to meet promises to stop the flow of the 
			synthetic opioid fentanyl into the United States.
 
 (Reporting by Roxanne Liu and Brenda Goh; editing by Darren 
			Schuettler)
 
			[© 2019 Thomson Reuters. All rights 
				reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published, 
			broadcast, rewritten or redistributed.  
			Thompson Reuters is solely responsible for this content. |